GLP-1 Drug Generations Compared: Semaglutide, Tirzepatide, Retatrutide, CagriSema, Amycretin, and Orforglipron
We are living through what many endocrinologists call the most significant revolution in metabolic medicine in a generation. The GLP-1 class of drugs has moved in just over two decades from injectable diabetes medications with modest weight effects to sophisticated molecules capable of producing 20–28% body weight reductions — numbers that rival bariatric surgery. But the generation currently dominating headlines (semaglutide, tirzepatide) is already being chased down by a next wave of drugs that are oral, monthly-dosed, or target entirely new receptor combinations. If you want to understand where this field is going — and what each generation actually does differently — this is the guide for you.
What Is a GLP-1 Receptor Agonist, and Why Does It Cause Weight Loss?
Before diving into the generational breakdown, it helps to understand the underlying biology. GLP-1, or glucagon-like peptide-1, is a hormone your gut naturally releases after eating. Its jobs include:
- Signaling the pancreas to release insulin (glucose-dependent — meaning it only works when blood sugar is elevated)
- Slowing gastric emptying (food moves more slowly from your stomach to your intestines)
- Acting on the hypothalamus (the brain's appetite control center) to reduce hunger signals
The result is that you feel fuller faster, eat less, and your blood sugar stays more stable. GLP-1 receptor agonists (GLP-1 RAs) are synthetic molecules that mimic this hormone — but better. Natural GLP-1 breaks down in the bloodstream in just 2 minutes. Drug versions are engineered to last hours, days, or even weeks.
The weight loss effect is primarily central and gastric: your brain receives prolonged "I'm full" signals, and food sits in your stomach longer, extending satiety. For people with obesity, this is transformative — it essentially dials down the amplified hunger signaling that makes sustained weight loss so difficult.
Generation 1: The Originals — Exenatide and Liraglutide
Exenatide (Byetta, Bydureon): The Proof of Concept
The story begins with an unlikely source: the saliva of the Gila monster lizard. Researchers discovered in the 1990s that a peptide in Gila monster venom — exendin-4 — bound human GLP-1 receptors with high affinity. This became exenatide, the first GLP-1 RA approved by the FDA in 2005 for type 2 diabetes.
Exenatide's weight loss effects were modest: approximately 2–3 kg on average. But it proved the concept. Twice-daily injections were inconvenient, and the short half-life meant patients had to time injections around meals. A longer-acting weekly formulation (Bydureon, exenatide extended-release) followed in 2012 but still showed limited efficacy compared to what was coming.
Target: GLP-1 receptor only
Route: Subcutaneous injection, twice daily (Byetta) or weekly (Bydureon)
Weight loss: ~2–3 kg on average
FDA approval: 2005 (Byetta), 2012 (Bydureon)
Liraglutide (Victoza, Saxenda): The First Obesity Approval
Novo Nordisk's liraglutide was a significant step up. By attaching a fatty acid chain to the GLP-1 peptide backbone, chemists created a molecule that bound to albumin in the bloodstream, extending its half-life to about 13 hours — enabling once-daily dosing. Victoza (1.8 mg) was approved for type 2 diabetes in 2010. At a higher dose (3 mg), it became Saxenda — the first GLP-1 RA specifically approved for chronic weight management in 2014.
Average weight loss with Saxenda at 3 mg was around 8% of body weight over 56 weeks in the SCALE trial — meaningful, but modest by today's standards. The FDA also approved a generic version of liraglutide (Saxenda) in August 2025.
Target: GLP-1 receptor only
Route: Subcutaneous injection, once daily
Weight loss: ~5–8% of body weight
FDA approval: 2014 (obesity indication)
Generation 2: The Breakthrough — Semaglutide
If liraglutide proved that GLP-1 could treat obesity, semaglutide proved it could transform it. Semaglutide (developed by Novo Nordisk) represented the same fatty-acid binding trick as liraglutide, but refined dramatically. A substitution at position 8 of the GLP-1 peptide sequence protects it from DPP-4 enzyme degradation, and a longer C18 fatty acid chain extends its half-life to approximately 7 days — enabling once-weekly dosing.
Ozempic and Wegovy: Two Doses, Two Indications
At the diabetes dose (0.5–2 mg weekly), semaglutide became Ozempic (FDA-approved 2017). The SUSTAIN trials showed A1c reductions of ~1.5% and weight loss averaging 4–6 kg.
The real explosion came with the obesity dose of 2.4 mg weekly, marketed as Wegovy. The STEP 1 trial — the pivotal study — showed an average weight loss of 14.9% at 68 weeks, with nearly a third of participants losing more than 20% of their body weight. For a weekly injection, these numbers were unprecedented. The STEP UP trial (2025) pushed even further, demonstrating 20.7% weight loss with a higher 7.2 mg dose.
Semaglutide also gained FDA approval in January 2025 for reducing the risk of chronic kidney disease progression in type 2 diabetes patients, adding to its growing list of cardiovascular and metabolic benefits first established in the SUSTAIN-6 and SELECT trials.
In December 2025, the FDA approved oral Wegovy — a 25 mg tablet formulation of semaglutide — making it the first oral GLP-1 receptor agonist approved specifically for weight management. (The earlier oral diabetes formulation, Rybelsus at 7–14 mg, had been approved in 2019 but required fasting administration with limited water.)
Target: GLP-1 receptor only
Route: Subcutaneous injection weekly (Ozempic/Wegovy) or oral daily (Rybelsus/oral Wegovy)
Weight loss: 14.9–20.7% depending on dose
FDA approval: 2017 (diabetes), 2021 (obesity)
Generation 3: Dual Agonism — Tirzepatide and the GIP Advantage
Here is where things get genuinely exciting. Eli Lilly's tirzepatide doesn't just activate GLP-1 receptors — it also activates GIP receptors (glucose-dependent insulinotropic polypeptide). GIP is another incretin hormone that, like GLP-1, is released after eating. For years, researchers thought GIP was relatively unimportant for weight loss — GIP receptor knockout mice are actually leaner, which confused everyone. But it turns out that activating GIP receptors in combination with GLP-1 produces synergistic metabolic effects that neither hormone achieves alone.
Mounjaro and Zepbound: The Dual Agonist Advantage
Tirzepatide (Mounjaro for diabetes, Zepbound for obesity) was approved by the FDA in 2022 for type 2 diabetes and 2023 for obesity. The SURMOUNT-1 trial — the pivotal obesity study — showed an astonishing average weight loss of 20.9% at the highest dose (15 mg weekly) over 72 weeks, with about half of participants losing 20% or more and approximately 1 in 5 losing 25% or more.
This represented the first drug to consistently outperform semaglutide in head-to-head comparisons. The SURMOUNT-5 trial confirmed this directly, showing tirzepatide produced approximately 47% more body weight loss than semaglutide at maximum doses.
Why does adding GIP matter? The current hypothesis is that GIP acts centrally to enhance the appetite-suppressive effects of GLP-1, and peripherally to reduce GI side effects — which may explain why tirzepatide is generally better tolerated than semaglutide despite producing more weight loss. The two pathways appear synergistic rather than simply additive.
Target: GLP-1 + GIP receptors (dual agonist)
Route: Subcutaneous injection, once weekly
Weight loss: ~20.9% at 15 mg (SURMOUNT-1)
FDA approval: 2022 (diabetes), 2023 (obesity)
Generation 4: Triple Agonism and Novel Combinations
We are now entering the era where drug designers are asking: what happens if we add a third — or even a fourth — receptor target?
Retatrutide: The Triple Agonist
Retatrutide (Eli Lilly) is the most potent GLP-1-based molecule yet tested. It activates three receptors: GLP-1, GIP, and glucagon receptors. The glucagon receptor addition is significant — glucagon normally raises blood sugar (the opposite of insulin), but it also powerfully increases energy expenditure in the liver and promotes fat burning. In the context of combined GLP-1/GIP co-agonism, the glucagon component appears to accelerate fat oxidation without the hyperglycemic downside.
Phase 3 results have been remarkable. The TRIUMPH-4 trial (December 2025) showed weight loss of up to 28.7% at 12 mg — the highest sustained weight loss ever documented in a randomized controlled trial for a pharmacologic agent. A Phase 3 T2D trial (TRANSCEND-T2D-1, March 2026) showed 16.8% weight loss in diabetic patients at 40 weeks, alongside up to 2.0% A1c reduction.
Target: GLP-1 + GIP + glucagon receptors (triple agonist)
Route: Subcutaneous injection, once weekly
Weight loss: Up to 28.7% (TRIUMPH-4, Phase 3)
Approval status: Phase 3; FDA submission expected 2026
CagriSema: Combining GLP-1 with Amylin
CagriSema (Novo Nordisk) takes a different approach. Rather than activating multiple incretin receptors, it combines semaglutide (GLP-1 RA) with cagrilintide — an amylin analog. Amylin is a peptide co-secreted with insulin from pancreatic beta cells. It reduces food intake through a different brain circuit than GLP-1 — primarily via the area postrema — and also slows gastric emptying independently.
The REDEFINE 1 trial (Phase 3, 68 weeks) showed 22.7% weight loss with CagriSema, significantly outperforming either semaglutide alone (16.1%) or cagrilintide alone (11.8%). However, this fell short of the 25% goal Novo Nordisk had set, and investors responded negatively. When tested head-to-head against tirzepatide in REDEFINE 4 (February 2026), CagriSema achieved 23% weight loss at 84 weeks compared to 25.5% with tirzepatide — close, but not non-inferior by statistical criteria.
Novo Nordisk submitted CagriSema for FDA approval in December 2025, making it potentially the first GLP-1/amylin combination product to reach the market.
Target: GLP-1 + amylin receptors
Route: Subcutaneous injection, once weekly
Weight loss: ~22.7–23% (REDEFINE 1/4, Phase 3)
Approval status: FDA submission December 2025; decision pending 2026
Generation 5: The Frontier — Oral Small Molecules, Unimolecular Designs, and Monthly Antibody Conjugates
This is the generation currently in late-stage development that could reshape how — and who — gets treatment.
Orforglipron: The First Oral Non-Peptide GLP-1 RA
Every GLP-1 drug approved before 2025 was either a peptide (requiring injection) or a peptide adapted for oral use with significant limitations. Oral semaglutide (Rybelsus) is a peptide requiring a special absorption enhancer (SNAC), must be taken on an empty stomach with only a small sip of water, and shows variable absorption.
Orforglipron (Eli Lilly) is fundamentally different: it is a small molecule — not a peptide. It works by binding the GLP-1 receptor through a mechanism similar to peptide agonists but using a completely different chemical structure that can survive the acidic, enzyme-rich gastrointestinal environment. No absorption enhancers. No fasting requirement. Just a daily pill.
The ACHIEVE-1 Phase 3 trial (results announced April 2025) showed orforglipron reduced A1c by an average of 1.3–1.6% across doses in type 2 diabetes patients, with body weight reductions of up to 7.9% at the highest dose (36 mg) at 40 weeks — and weight loss had not plateaued at study end. A separate Phase 3 weight management program (ATTAIN trials) is underway.
Critically for patients: the Attain-Maintain trial (December 2025) showed orforglipron can maintain weight loss in people previously treated with injectable incretins (Wegovy or Zepbound), positioning it as a potential long-term oral maintenance option after achieving weight goals via injection.
Lilly expects to submit orforglipron for diabetes approval in 2025–2026 and for weight management by end of 2025, with FDA decisions expected in 2026.
Target: GLP-1 receptor
Route: Oral daily tablet (no fasting requirement)
Weight loss: Up to 7.9% at 40 weeks in T2D Phase 3 (ACHIEVE-1); weight management data pending
Approval status: FDA submission 2025–2026; decision expected 2026
Amycretin: The Unimolecular GLP-1 + Amylin Agonist
Amycretin (Novo Nordisk) is one of the most scientifically innovative molecules in the pipeline. Unlike CagriSema — which is a co-formulation of two separate molecules (semaglutide + cagrilintide) — amycretin is a single unimolecular compound that simultaneously activates both GLP-1 and amylin receptors in one molecule.
This matters for several reasons. A single molecule has simpler pharmacokinetics (predictable half-life, consistent dosing), potentially different receptor interaction dynamics, and may offer manufacturing and dosing advantages long-term.
The Phase 1b/2a data, published in The Lancet and presented at ADA 2025 (June 2025), showed subcutaneous amycretin produced up to 22% average weight loss over 36 weeks in people with obesity — with no weight loss plateau observed. A subsequent Phase 2 trial in type 2 diabetes (results announced November 2025) showed up to 14.5% weight loss and up to 1.8% A1c reduction at 36 weeks, with 89.1% of participants achieving A1c below 7%.
Notably, amycretin also exists in an oral formulation, which showed up to 13.1% weight loss at 12 weeks in a Phase 1 study — remarkable for an oral agent at that short timeframe. Novo Nordisk is advancing amycretin to Phase 3 trials based on this data.
Target: GLP-1 + amylin receptors (unimolecular)
Route: Subcutaneous weekly injection or oral daily (both in development)
Weight loss: Up to 22% SC (Phase 2 obesity); up to 14.5% SC (Phase 2 T2D); up to 13.1% oral (Phase 1, 12 weeks)
Approval status: Phase 3 initiation 2025–2026
MariTide (Maridebart Cafraglutide): Monthly Dosing via Antibody Conjugate
MariTide (Amgen) represents an entirely different engineering philosophy. Rather than a small peptide or small molecule, MariTide is a bispecific peptide-antibody conjugate: a monoclonal antibody linked to GLP-1 receptor agonist and GIP receptor antagonist peptides. The antibody backbone dramatically extends the molecule's half-life — enabling monthly or even less frequent dosing.
The full Phase 2 results were presented at ADA 2025 (June 2025) and simultaneously published in the New England Journal of Medicine. In people with obesity without type 2 diabetes, MariTide produced up to approximately 20% average weight loss at 52 weeks (per the efficacy estimand), with no plateau observed. In people with obesity and type 2 diabetes, weight loss reached approximately 17%, alongside robust HbA1c reductions of up to 2.2%.
The significant caveat: virtually all participants experienced gastrointestinal adverse events, and up to 27% discontinued treatment in some groups — a tolerability challenge that Amgen is addressing with improved dose escalation strategies for Phase 3. Amgen also noted a greater than 70% reduction in high-sensitivity CRP (a marker of systemic inflammation), suggesting MariTide has anti-inflammatory effects beyond weight loss.
MariTide is unique in that it antagonizes GIP receptors (unlike tirzepatide and retatrutide, which activate them). This reflects the longstanding GIP receptor controversy: paradoxically, both GIP agonism (tirzepatide) and GIP antagonism (MariTide) produce substantial weight loss, suggesting the GIP system's role in energy homeostasis is more complex than a simple on/off switch.
Target: GLP-1 receptor agonist + GIP receptor antagonist (bispecific antibody conjugate)
Route: Subcutaneous injection, monthly (or less frequently)
Weight loss: Up to ~20% at 52 weeks (Phase 2, obesity cohort)
Approval status: Phase 2 complete; Phase 3 expected 2025–2026
Comprehensive GLP-1 Drug Comparison Table
| Drug | Manufacturer | Target Receptors | Route | Dosing Frequency | Approval Status | Best Weight Loss Result |
|---|
| Exenatide (Byetta/Bydureon) | AstraZeneca | GLP-1 | SC injection | Twice daily / Weekly | FDA-approved (2005/2012) | ~3–5% |
| Liraglutide (Saxenda) | Novo Nordisk | GLP-1 | SC injection | Daily | FDA-approved (2014) | ~8% |
| Semaglutide SC (Wegovy) | Novo Nordisk | GLP-1 | SC injection | Weekly | FDA-approved (2021) | ~20.7% (STEP UP, 7.2 mg) |
| Oral Semaglutide (Rybelsus/oral Wegovy) | Novo Nordisk | GLP-1 | Oral tablet | Daily | FDA-approved (2019/Dec 2025) | ~17% (oral Wegovy) |
| Tirzepatide (Zepbound) | Eli Lilly | GLP-1 + GIP | SC injection | Weekly | FDA-approved (2023) | ~20.9% (SURMOUNT-1) |
| Retatrutide | Eli Lilly | GLP-1 + GIP + Glucagon | SC injection | Weekly | Phase 3 | ~28.7% (TRIUMPH-4) |
| CagriSema | Novo Nordisk | GLP-1 + Amylin | SC injection | Weekly | FDA submission Dec 2025 | ~23% (REDEFINE 4) |
| Amycretin (SC) | Novo Nordisk | GLP-1 + Amylin (unimolecular) | SC injection | Weekly | Phase 3 initiation 2025–2026 | ~22% (Phase 2, 36 wks) |
| Amycretin (oral) | Novo Nordisk | GLP-1 + Amylin (unimolecular) | Oral tablet | Daily | Phase 2/3 | ~13.1% (Phase 1, 12 wks) |
| Orforglipron | Eli Lilly | GLP-1 (small molecule) | Oral tablet | Daily | FDA submission 2025–2026 | ~7.9% T2D (ACHIEVE-1, 40 wks; weight mgmt data pending) |
| MariTide | Amgen | GLP-1 agonist + GIP antagonist | SC injection | Monthly (or less) | Phase 2 complete | ~20% (Phase 2, 52 wks) |
What Each Generational Leap Actually Means for Patients
More Efficacy: Approaching Surgical Weight Loss Numbers
First-generation GLP-1 drugs produced weight losses of 3–8% — meaningful for diabetes management but underwhelming for obesity treatment. Semaglutide cracked 15%, tirzepatide pushed to 21%, retatrutide is now demonstrating nearly 29%. For context, Roux-en-Y gastric bypass typically produces 25–35% total body weight loss. We are approaching pharmacological parity with surgery.
This matters because surgery is irreversible, requires general anesthesia, carries complication risks, and is unavailable or unacceptable to most people with obesity. A weekly injection that achieves similar numbers — without operating rooms — represents a genuine paradigm shift.
Broader Receptor Targeting: Beyond Blood Sugar
The move from GLP-1 monotherapy to dual and triple agonism isn't just about hitting harder — it's about hitting smarter. Adding GIP creates synergistic effects. Adding glucagon increases energy expenditure. Adding amylin engages a completely separate appetite circuit. Each new target addresses a different mechanism of energy dysregulation, and in combination they appear to produce effects greater than the sum of their parts.
This also means next-generation drugs may be effective for patients who responded poorly to semaglutide — because they're engaging different biological pathways.
More Convenient Dosing: From Daily Injections to Monthly
The shift from twice-daily injections (exenatide) to weekly (semaglutide, tirzepatide) already improved adherence dramatically. Monthly dosing (MariTide) would be transformative for long-term compliance — similar to how once-monthly osteoporosis drugs improved that field. An oral daily pill (orforglipron, oral amycretin) removes the injection barrier entirely, potentially opening treatment to tens of millions of people who won't self-inject.
Potentially Better Side Effect Profiles
GI side effects — nausea, vomiting, constipation — are the primary reason people stop GLP-1 drugs. There's evidence that dual agonists like tirzepatide may have a better GI tolerability profile than semaglutide, possibly because the GIP component moderates gastric effects. Next-gen molecules may continue this trend. MariTide's current tolerability challenges are being actively addressed in Phase 3 design.
The Pipeline Outlook: 2025–2027
Looking ahead, several key milestones are expected:
2025–2026:
- Orforglipron FDA approval (diabetes indication likely first, followed by weight management)
- CagriSema FDA decision (submitted December 2025)
- Retatrutide Phase 3 completion and likely FDA submission
- Amycretin Phase 3 trials begin
2026–2027:
- Retatrutide FDA approval decision (first triple agonist to market)
- MariTide Phase 3 results and potential FDA submission
- Oral amycretin Phase 2/3 data readout
- High-dose CagriSema (2.4 mg/7.2 mg) Phase 3 initiation
- Potential first approvals in additional indications: heart failure, sleep apnea, chronic kidney disease, NASH/MASH
The competitive landscape is also broadening. Chinese pharmaceutical companies have several GLP-1 candidates in development with potential for global competition. Additional small-molecule GLP-1 RAs from multiple companies are in early-stage trials. The race to find an oral formulation with efficacy matching injectable semaglutide is intense.
One emerging frontier: GLP-1 plus something entirely outside the incretin family. Researchers are exploring combinations with amyloid-targeting molecules (for Alzheimer's prevention), fibroblast growth factor analogs (FGF21), and integrin-targeting compounds — the GLP-1 receptor has become a scaffold for delivering and enhancing entirely new therapeutic strategies.
Frequently Asked Questions
Q: What is the most effective GLP-1 drug currently available?
A: As of 2025–2026, tirzepatide (Zepbound) at 15 mg weekly is the most effective FDA-approved GLP-1-based medication for obesity, achieving approximately 20.9% average body weight loss in the SURMOUNT-1 Phase 3 trial. Retatrutide has shown up to 28.7% in Phase 3 trials but has not yet received FDA approval. The "most effective" answer will shift as new approvals occur.
Q: What makes retatrutide different from tirzepatide?
A: Tirzepatide is a dual agonist that activates GLP-1 and GIP receptors. Retatrutide adds a third target — the glucagon receptor — making it a triple agonist. The glucagon activation increases energy expenditure in the liver and accelerates fat burning, contributing to the higher weight loss observed (up to 28.7%) compared to tirzepatide (~20.9%).
Q: Is orforglipron the same as oral semaglutide (Rybelsus)?
A: No. Oral semaglutide (Rybelsus) is a peptide that requires special absorption technology, must be taken on a completely empty stomach with minimal water, and has variable absorption. Orforglipron is a non-peptide small molecule that survives digestion on its own — no fasting requirement, standard oral bioavailability. This is a fundamentally different approach that may achieve much higher patient compliance.
Q: What is amycretin and how does it differ from CagriSema?
A: Both amycretin and CagriSema target GLP-1 and amylin receptors. The difference is structural: CagriSema is a co-formulation of two separate molecules (semaglutide + cagrilintide), while amycretin is a single unimolecular compound that activates both receptors simultaneously. Amycretin also comes in both injectable and oral formulations. Phase 2 data showed amycretin achieved up to 22% weight loss in obesity over 36 weeks.
Q: How does MariTide achieve monthly dosing?
A: MariTide (maridebart cafraglutide) is a bispecific peptide-antibody conjugate. The monoclonal antibody backbone dramatically extends the molecule's half-life compared to standard peptide GLP-1 drugs, enabling subcutaneous injections once monthly or less frequently. This is fundamentally different engineering from the fatty-acid binding approach used by liraglutide and semaglutide.
Q: Does MariTide activate or block GIP receptors?
A: MariTide antagonizes (blocks) GIP receptors, while tirzepatide activates them. Paradoxically, both approaches produce substantial weight loss — a finding that has fascinated researchers. This suggests the GIP system's role in energy balance is more complex than a simple activation-inhibition model, and that blocking GIP may prevent GIP's potential to counteract GLP-1's beneficial effects in some contexts.
Q: What percentage of weight loss is typical muscle vs. fat on GLP-1 drugs?
A: Clinical trials consistently show that approximately 60–75% of weight lost on GLP-1 drugs is fat mass, with 25–40% being lean mass. This lean mass loss is broadly proportional to what occurs with any form of significant caloric restriction and can be substantially reduced with adequate protein intake (1.6–2.2 g/kg/day) and resistance training.
Q: Why did CagriSema disappoint investors despite 22–23% weight loss?
A: CagriSema's REDEFINE 4 trial showed 23% weight loss — impressive by historical standards — but failed to demonstrate statistical non-inferiority to tirzepatide's 25.5%. Additionally, early investor expectations were for 25% or greater weight loss from CagriSema. The drug still represents a significant achievement and was submitted for FDA approval in December 2025, but the competitive landscape has set very high benchmarks.
Q: Which next-generation GLP-1 drugs might reach the US market by 2027?
A: The most likely approvals by 2027 include: CagriSema (FDA submission December 2025; decision likely 2026), orforglipron (FDA submission 2025–2026; diabetes approval first, then obesity), and retatrutide (Phase 3 complete; FDA submission expected 2026, decision 2026–2027). MariTide may receive FDA submission in 2026–2027 pending Phase 3 results.
Q: Is there an oral GLP-1 drug that works without fasting?
A: Yes — orforglipron. Unlike oral semaglutide (Rybelsus), which requires an empty stomach and limited water intake, orforglipron is a small-molecule oral tablet with no fasting requirement. It completed the ACHIEVE-1 Phase 3 trial with positive results and is expected to receive FDA approval in 2026. Oral amycretin is also in development and showed promising Phase 1 weight loss data.
Q: What is the mechanism behind the GLP-1 + amylin combination's extra weight loss?
A: GLP-1 and amylin reduce food intake through different neurological circuits. GLP-1 primarily acts on receptors in the hypothalamus and vagal nerve pathways, while amylin acts via the area postrema (a brainstem region outside the blood-brain barrier). Combining them creates complementary satiety signaling that neither can achieve alone, explaining why CagriSema and amycretin outperform semaglutide monotherapy in head-to-head comparisons.
Q: Will GLP-1 drugs eventually replace bariatric surgery?
A: Not entirely, but the gap is narrowing. Retatrutide's Phase 3 results showing 28.7% weight loss approach the lower range of surgical outcomes. However, surgery also alters gut anatomy in ways that benefit metabolism independently of weight, and some patients achieve more durable weight loss with surgery. The more likely scenario is that next-generation GLP-1 drugs will dramatically reduce the need for surgery and become the preferred first-line treatment for most patients with severe obesity.
Key Takeaways
-
GLP-1 drugs have evolved from modest diabetes aids to near-surgical weight loss agents in approximately two decades, with efficacy increasing from ~3% (exenatide) to ~28.7% (retatrutide Phase 3) body weight loss.
-
Generational progression follows receptor targeting: single agonists (GLP-1 only) → dual agonists (GLP-1 + GIP) → triple agonists (GLP-1 + GIP + glucagon) → unimolecular combinations (GLP-1 + amylin).
-
Semaglutide (weekly SC, oral) remains the market leader with strong cardiovascular, renal, and metabolic data. Tirzepatide has demonstrated superior weight loss in head-to-head data.
-
Retatrutide is the most potent drug tested to date (28.7% weight loss, Phase 3) and is on track for FDA submission in 2026.
-
Orforglipron is the first oral non-peptide GLP-1 RA, requiring no fasting, and represents a potential access revolution — making treatment available to the many people who won't inject.
-
Amycretin (Novo Nordisk) is the first unimolecular GLP-1/amylin agonist, showing up to 22% weight loss in Phase 2, available in both SC and oral forms.
-
MariTide (Amgen) offers monthly dosing via an antibody-conjugate design and showed ~20% weight loss in Phase 2, addressing the adherence challenge of chronic therapy.
-
By 2027, patients may choose from weekly injectables, monthly injectables, and oral daily pills — with efficacy across the entire range matching or exceeding current surgical benchmarks.
Citations & References
-
Wilding JPH, et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1). New England Journal of Medicine. 2021;384(11):989-1002. https://pubmed.ncbi.nlm.nih.gov/33567185/
-
Jastreboff AM, et al. Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1). New England Journal of Medicine. 2022;387(3):205-216. https://pubmed.ncbi.nlm.nih.gov/35658024/
-
Eli Lilly. TRIUMPH-4 Phase 3 Trial Results: Retatrutide. Press Release. December 2025. https://www.clinicaltrialsarena.com/news/lilly-retatrutide-data-phase-iii-trial/
-
Eli Lilly. ACHIEVE-1 Phase 3 Trial Results: Orforglipron. Press Release. April 2025. https://www.prnewswire.com/news-releases/lillys-oral-glp-1-orforglipron-demonstrated-statistically-significant-efficacy-results-and-a-safety-profile-consistent-with-injectable-glp-1-medicines-in-successful-phase-3-trial-302430985.html
-
Novo Nordisk. Amycretin Phase 2 Trial Results in Type 2 Diabetes. November 2025. https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=916463
-
BioSpace. Amycretin Phase 1b/2a Obesity Data — ADA 2025 Presentation. June 2025. https://www.biospace.com/press-releases/novo-nordisks-subcutaneous-and-oral-amycretin-data-published-in-the-lancet-and-presented-at-ada-2025
-
Amgen. MariTide Phase 2 Results Press Release (ADA 2025). June 2025. https://www.prnewswire.com/news-releases/results-from-amgens-phase-2-obesity-study-of-monthly-maritide-presented-at-the-american-diabetes-association-85th-scientific-sessions-302487811.html
-
Jastreboff AM, et al. MariTide Phase 2 Trial Results. New England Journal of Medicine. 2025. https://www.medscape.com/viewarticle/once-monthly-maritide-promising-phase-2-despite-gi-issues-2025a1000h50
-
Novo Nordisk. REDEFINE 1 Phase 3 CagriSema Results. December 2024. https://www.clinicaltrialsarena.com/news/novo-nordisks-cagrisema-outperforms-ozempic-in-phase-iii-trial/
-
Novo Nordisk. REDEFINE 4 Phase 3 CagriSema vs. Tirzepatide. February 2026. https://www.biospace.com/press-releases/novo-nordisk-a-s-cagrisema-demonstrated-23-weight-loss-in-an-open-label-head-to-head-redefine-4-trial-in-people-with-obesity-the-primary-endpoint-was-not-achieved
-
Eli Lilly. Orforglipron Attain-Maintain Phase 3 Results. December 2025. https://www.pharmexec.com/view/eli-lilly-announces-topline-results-phase-iii-trial-studying-oral-glp-therapy-orforglipron
-
Davies M, et al. CagriSema in Type 2 Diabetes — REIMAGINE 2. ADA 2025. https://www.pharmacytimes.com/view/ada-2025-cagrisema-demonstrates-significant-weight-loss-in-redefine-clinical-trials
-
Eli Lilly. TRANSCEND-T2D-1 Phase 3 Retatrutide in T2D. March 2026. https://lilly.gcs-web.com/news-releases/news-release-details/lillys-triple-agonist-retatrutide-demonstrated-significant
-
Nauck MA, D'Alessio DA. Tirzepatide, a dual GIP/GLP-1 receptor co-agonist for the treatment of type 2 diabetes with unmatched effectiveness regrading glycaemic control and body weight reduction. Cardiovascular Diabetology. 2022;21:169. https://pubmed.ncbi.nlm.nih.gov/36038870/
-
American Diabetes Association. ADA 85th Scientific Sessions Press Release — Next-Generation GLP-1 Data. June 2025. https://professional.diabetes.org/sites/dpro/files/2025-06/updatedADA2025Next%20GenerationGLP-1PressRelease_FINAL.pdf
